Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
IBM reports Q3 results on October 21 with short interest continuing to build quietly against a stock that has recovered ground this week but remains down sharply on the year.
The short positioning picture is essentially unchanged from Wednesday's note: shorts added another 0.6% on October 15, taking the weekly build to roughly 9.7% and the one-month increase to 14%. Short interest now stands at 23.4 million shares, or 2.5% of the free float. That is still a low absolute level, and the lending market offers no amplification. Availability remains extraordinarily loose at 7,518% of short interest, meaning there are dozens of shares available to borrow for every one already lent out. The cost to borrow, at 0.40%, has eased on the week. Bears are adding into earnings, but they are doing so cheaply and without constraint. Options confirm the lack of urgency: the put/call ratio of 0.83 is almost exactly in line with its 20-day average, and the z-score is near zero. There is no defensive hedging spike, no premium being paid for downside protection.
The fundamental debate is straightforward, and both sides have data to lean on. Bulls point to a recurring revenue base approaching 80% of software revenue, accelerating ARR, record z17 mainframe demand, and management's maintained free cash flow guidance of $15.7 billion for the year. The argument is that the consulting weakness is transitory and that IBM's hybrid cloud and AI positioning allows it to grow through enterprise modernisation cycles. Bears focus on the July guidance cut to 4 to 5% constant-currency revenue growth, limited visibility into the second half, and mainframe exposure that represents roughly 20% of revenue, where transaction processing revenue is estimated to have fallen 10 to 12% year-on-year in the quarter. Morgan Stanley's Erik Woodring raised his target sharply, from $190 to $238, just last Thursday, while Truist initiated at Hold with a $240 target earlier this month. RBC held its Outperform and $270 target. The Street is not abandoning IBM, but the consensus at $243 implies modest upside from the current $232 level, and most of the neutral and equal-weight voices are clustered around current prices.
The last two earnings reactions are instructive. July's Q2 print produced a 1.8% one-day drop followed by a 7.6% five-day recovery, as the initial disappointment gave way to buyers taking the dip. April's Q1 event was almost a non-event, down 0.4% on the day and up 0.4% over five days. Neither print triggered a violent move in either direction, which is consistent with the subdued options positioning ahead of Wednesday's release.
The October 21 print will test whether management can demonstrate that the July guidance cut marked the floor rather than the beginning of a prolonged earnings reset, and whether consulting demand has stabilised enough to restore any confidence in the second-half trajectory.
See the live data behind this article on ORTEX.
Open IBM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
